Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

This study has been completed.
Sponsor:
Collaborators:
Ministry of Health, China
Hepatic Surgery Clinical Research Centre of Hubei, China
Information provided by:
Huazhong University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00733200
First received: August 8, 2008
Last updated: December 10, 2009
Last verified: August 2008
  Purpose

The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma. In selected patients, minor liver resection was a good treatment.


Condition Intervention
Cholangiocarcinoma
Surgical Treatment
Hepatectomy
Procedure: Minor or Major Liver Resection

Study Type: Interventional
Official Title: Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

Resource links provided by NLM:


Further study details as provided by Huazhong University of Science and Technology:

Primary Outcome Measures:
  • On multivariate analysis, prognostic factors significantly impacted on long-term survival were UICC tumor stage and histopathologic grade.

Arms Assigned Interventions
No Intervention: Control group Procedure: Minor or Major Liver Resection

Detailed Description:

Objective: To determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in patients with hilar cholangiocarcinoma (HC).

Summary Background Data: For HC treated with hepatectomy, the extent of liver resection remains controversial despite extensive studies.

Methods: From January 2000 to December 2007, we prospectively studied patients who received surgical treatment for HC. Of the 187 patients who were surgically treated, 138 (73.8%) underwent resection with a curative intent. Minor hepatectomy was carried out in 93 patients who had Bismuth-Corlette types I, II and III HC without hepatic artery/portal vein invasion; and major hepatectomy in 45 patients who had type III HC with hepatic artery/portal vein invasion, or type IV HC.

  Eligibility

Ages Eligible for Study:   26 Years to 72 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Criteria for resectability were absence of peritoneal or liver metastases, tumor extension to beyond secondary biliary branches bilaterally, tumor extension to secondary portal venous branches bilaterally

Exclusion Criteria:

  • not in accordance with the above criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00733200     History of Changes
Other Study ID Numbers: chenxp002
Study First Received: August 8, 2008
Last Updated: December 10, 2009
Health Authority: China: Food and Drug Administration

Keywords provided by Huazhong University of Science and Technology:
Minor Liver Resection
Major Liver Resection
Hilar

Additional relevant MeSH terms:
Cholangiocarcinoma
Klatskin's Tumor
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms

ClinicalTrials.gov processed this record on July 29, 2014